Abstract

This study aimed to investigate the effects of Nephropathy Prescription I on the expression of angptl3, nephrin, and podocin, in addition to its protective effects on podocytes in mice with adriamycin-induced nephropathy. BALB/c mice were randomly divided into the control (C), adriamycin (Model or M), adriamycin + Nephropathy Prescription I (M + Z), adriamycin + prednisone acetate (M + S), and adriamycin + Nephropathy Prescription I + prednisone acetate groups (M + Z + S). All mice except those in the C group in the experimental groups were treated with a single tail vein injection of adriamycin. The urine albumin-creatinine ratio was measured before model establishment and on the 7th day, 14th day, 21st day, and 28th day of doxorubicin injection. All the mice were sacrificed on the 29th day. Blood samples were collected to observe biochemical indicators in the serum. The morphological structure and podocyte ultrastructure in the kidney were observed using light and electron microscopy, respectively. The expression of angptl3, nephrin, and podocin at the mRNA and protein levels was detected by real-time PCR and western blotting, respectively. Following modeling with adriamycin, albuminuria was observed in urine samples in the first week, and the urinary protein/creatinine ratio increased maximally in the fourth week in the M group (P < 0.05). In contrast, the urinary protein/creatinine ratio significantly decreased (P < 0.05) in the third week in the (M + Z) group compared to that in the M group. Similarly, this ratio decreased in the (M + S) and (M + Z + S) groups compared to that in the M group throughout the experiment. Compared with the C group, serum albumin content and the expression of nephrin and podocin decreased (P < 0.05), whereas blood lipid level and the expression of angptl3 increased (P < 0.05) in the M group. Glomerular foot process fusion was observed in this group using electron microscopy. In all the intervention groups, serum albumin content and the expression of nephrin and podocin increased (P < 0.05), whereas blood lipid level and the expression of angptl3 decreased (P < 0.05), with alleviated glomerular foot process injury observed particularly in the (M + Z + S) group. The Nephropathy Prescription I can alleviate albuminuria, increase serum albumin levels, lower blood lipid levels, and reduce the fusion of foot processes of podocytes in mice with adriamycin-induced nephropathy. The protective effects of the Nephropathy Prescription I may function by reducing Angptl3 expression and increasing nephrin and podocin expression.

Highlights

  • Primary nephrotic syndrome (PNS) is a common kidney disease in children. e main clinical manifestations are proteinuria, hypoproteinemia, hyperlipidemia, and edema

  • Nephrotic syndrome belongs to the category of “edema” in Chinese medicine

  • In a mouse model with adriamycin-induced nephrotic syndrome, we investigated the effects of Nephropathy Prescription I on the biochemistry, pathology, and podocyte-related protein levels, providing evidence for its mechanism of action in treating children with nephrotic syndrome

Read more

Summary

Introduction

Primary nephrotic syndrome (PNS) is a common kidney disease in children. e main clinical manifestations are proteinuria, hypoproteinemia, hyperlipidemia, and edema. E main clinical manifestations are proteinuria, hypoproteinemia, hyperlipidemia, and edema. Primary nephrotic syndrome (PNS) is a common kidney disease in children. It has a prevalence of 12–16 per 100,000 children, with an annual incidence of 2–7 per 100,000 children. A large amount of proteinuria is the most characteristic clinical manifestation and an independent risk factor directly affecting the progression of renal disease [1, 2]. Erefore, hormone therapy is the first choice for Evidence-Based Complementary and Alternative Medicine the treatment of kidney diseases in clinical practice. Treatment of childhood nephrotic syndrome with hormones and/or immunosuppressants and biologics has certain toxic and side effects

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call